What are the significant effects of Alpelisib in treatment?

Alpelisib (Alpelisib)-Piqray is a milestone in the targeted treatment of breast cancer, especially the treatment of people with PIK3CA gene mutations. By specifically inhibiting the PI3Kα pathway, the drug fundamentally blocks the signaling chain of tumor cells and prevents further spread of tumors. For those patients who have received multiple lines of endocrine therapy but with poor results, the addition of apelvis significantly improves the treatment response rate and disease control rate. Its biggest feature is "accurate matching", that is, after confirming the PIK3CA mutation through genetic testing, personalized medicine can be used to make the treatment more targeted.

In international studies, the regimen of apelvis combined with fulvestrant has shown obvious clinical advantages. Patients with PIK3CA mutant breast cancer who received this regimen had significantly longer disease control times, increased tumor shrinkage rates, and delayed the progression of drug resistance. This means that Apelvis can not only improve the biological behavior of tumors, but also prolong the progression-free survival of patients, providing new hope for patients with hormone receptor-positive breast cancer. Compared with traditional chemotherapy, the side effects of Apelvis are controllable. Common adverse reactions such as hyperglycemia, rash or mild diarrhea can mostly be improved through monitoring and dose adjustment, and the overall tolerance is good.

In addition, the application scope of Apelix is constantly expanding. In addition to breast cancer, scientists are also exploring its potential role in other solid tumors related to PI3K pathway abnormalities, such as ovarian cancer, endometrial cancer, etc. A number of international clinical studies are ongoing, and the results show that its prospects in combination with other targeted drugs or immunotherapies are worth looking forward to.

For patients, the significant effect of Apelvis is not only reflected in prolonged survival time, but more importantly, improved quality of life. By inhibiting tumor growth and delaying the progression of recurrence, patients can maintain long-term treatment in a more stable state.

Reference materials:https://www.piqray.com/